Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies

Multiple sclerosis (MS) therapy has evolved rapidly with an increased availability of several immunomodulating therapies over the past two decades. Disease-modifying therapies have proven to be effective in treating relapse–remitting MS (RRMS). However, clinical trials involving some of the same age...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Jenny J, Ontaneda, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053100/
https://www.ncbi.nlm.nih.gov/pubmed/30050376
http://dx.doi.org/10.2147/DNND.S100096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053100/
https://www.ncbi.nlm.nih.gov/pubmed/30050376
http://dx.doi.org/10.2147/DNND.S100096

Ejemplares similares